go-v.orgdoi

Replication Data for "Quantum-capacitance biosensing enables real-time monitoring of naxitamab for therapeutic response stratification in neuroblastoma".

Andy Bruno, Ruslán Álvarez-Diduk, Paula Lara, Gabriel Maroli, Carlos J. Rodríguez-Hernández, Arben Merkoçi · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · 2026

  • DOI 10.34810/data3517
  • Publisher Consejo Superior de Investigaciones Científicas
  • Type dataset
  • Issued 2026

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

DIGITAL.CSIC (Spanish National Research Council (CSIC)) · Consejo Superior de Investigaciones Científicas · dataset · 2026

Abstract

Neuroblastoma, a leading cause of cancer-related mortality in early childhood, relies on anti-GD2 immunotherapy, whose efficacy is critically dependent on systemic drug exposure that remains largely unmonitored in real time, limiting treatment optimization and early response assessment. Here, a first-in-class, label-free electrochemical biosensing platform is reported for the direct quantification of naxitamab in patient-derived samples.

The system is based on a laser-assisted reduced graphene oxide–gold nanoparticle (rGO@AuNPs) nanocomposite, enabling ultrasensitive detection through quantum capacitance modulation arising from perturbations in the electronic density of states of graphene upon biomolecular recognition. Laser-assisted fabrication yields nanostructured electrodes with enhanced surface area and conductivity, promoting stable antibody immobilization and reproducible signal transduction. The platform operates in the femtomolar regime, with a linear response between 25 and 300 fM, high specificity against relevant interferents, and robust performance in diluted human serum.

A single-point calibration strategy enables accurate quantification while compensating for device variability. Application to retrospective clinical samples reveals distinct post-infusion concentration profiles, enabling early discrimination between responder groups and detection of anti-drug antibody development. This work establishes quantum-capacitance biosensing as a generalizable strategy for real-time monitoring of therapeutic antibodies in precision oncology.

Open the resolved locator · 10.34810/data3517

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 01:18 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
http://hdl.handle.net/10261/445061
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.